Vagus Nerve Stimulation

Vagus nerve stimulation (VNS) is the longest-established and most widely implanted neurostimulation therapy for drug-resistant epilepsy. Approved in Europe in 1994 and in the United States in 1997, VNS provides palliative seizure reduction through intermittent electrical stimulation of the left vagus nerve. Unlike resective surgery, VNS does not carry the risk of permanent neurologic deficits and is applicable to patients with generalized, multifocal, or non-localizable epilepsy who are not candidates for focal resection. Over three decades of clinical experience and more than 130,000 implantations worldwide have established VNS as a safe and moderately effective treatment option. Newer generator models with autostimulation capability (closed-loop heart rate detection) and refined programming strategies have incrementally improved outcomes. Although seizure freedom with VNS is uncommon (2–8%), the therapy provides meaningful seizure reduction in approximately half of treated patients and offers additional benefits in mood and quality of life.

Mechanism of Action

Anatomy of Vagal Afferents

The vagus nerve (CN X) is a mixed nerve with ~80% afferent (sensory) fibers. The left vagus nerve is chosen for VNS because it has less cardiac innervation than the right vagus, reducing the risk of cardiac arrhythmias. Vagal afferents terminate in the nucleus tractus solitarius (NTS) in the medulla, which serves as a relay hub to multiple brain regions involved in seizure modulation:

• Locus coeruleus: Source of noradrenergic projections to the cortex and hippocampus; norepinephrine has antiseizure properties through modulation of cortical excitability
• Raphe nuclei: Serotonergic projections; serotonin modulates cortical excitability and may contribute to antiseizure and antidepressant effects
• Thalamus: Relay to widespread thalamocortical networks; modulation of thalamocortical synchronization may reduce seizure propagation
• Limbic structures: Amygdala and hippocampal connections; may underlie mood and memory effects of VNS

Proposed Antiseizure Mechanisms

Implantation Procedure

Device Components

The VNS system consists of a pulse generator (battery-powered, programmable) implanted subcutaneously in the left infraclavicular chest wall and a bipolar helical lead attached to the left cervical vagus nerve. A handheld programming wand and tablet allow the clinician to adjust parameters, and a patient magnet enables on-demand stimulation.

Surgical Technique

• Approach: Two incisions—one in the left neck (along the anterior border of the sternocleidomastoid) and one in the left infraclavicular area; performed under general anesthesia, typically as an outpatient or single overnight stay
• Lead placement: The vagus nerve is identified in the carotid sheath between the internal jugular vein and common carotid artery; three helical coils are wrapped around the nerve (two stimulating electrodes and one anchor)
• Generator placement: The pulse generator is tunneled subcutaneously from the neck to the chest pocket
• Lead impedance testing: Performed intraoperatively to confirm proper electrode contact and circuit integrity
• Activation: The device is typically activated 2–4 weeks after implantation to allow wound healing
• Battery life: 3–11 years depending on the model and stimulation parameters; generator replacement is a simpler procedure (chest incision only)

Programming Parameters

Efficacy

Seizure Reduction

VNS provides meaningful but rarely complete seizure control. Key efficacy data include:

• Initial pivotal trials (E03, E05): Randomized, controlled, blinded trials comparing high stimulation vs. low stimulation (sham-like); modest but statistically significant seizure reduction in the high-stimulation group
• Meta-analysis of 74 studies: Median seizure frequency reduction of 36% at 3 months and 51% after 1 year of treatment
• 50% responder rate: Approximately 50% of patients achieve ≥50% seizure reduction by 1–2 years
• Seizure freedom: 2–5% at 4 months; 0–8% at long-term follow-up; VNS is not a curative therapy
• Progressive improvement: Seizure reduction increases during the first 1–2 years, consistent with long-term neuromodulatory effects rather than merely an acute stimulation effect

Predictors of Response

Magnet Use for Seizure Abortion

The patient or a caregiver can swipe a magnet over the generator to deliver an on-demand burst of stimulation at the onset of a seizure or aura. The magnet-triggered stimulation uses a higher output current than the standard cycling and can be set with longer ON time. Clinical evidence supporting acute seizure abortion with magnet use is limited but many patients and families report subjective benefit, particularly in shortening seizure duration or reducing seizure severity. The magnet can also be used to temporarily turn off stimulation (by holding it over the generator) during activities where stimulation-related side effects are problematic (e.g., singing, public speaking).

Side Effects and Complications

Stimulation-Related Side Effects

• Voice changes/hoarseness: Most common side effect (62% of patients); occurs only during the ON phase of stimulation; typically improves with acclimatization and can be mitigated by reducing output current
• Cough: Common during initial titration; usually improves over time
• Throat pain/tingling: Occurs in a minority; related to direct vagal stimulation
• Dyspnea: Rare; usually mild and related to laryngeal stimulation effects
• Headache: Reported in some patients; may be related to trigeminal-vagal reflex interactions

Surgical Complications

Autostimulation: Closed-Loop VNS

Heart Rate-Based Seizure Detection

Newer VNS generator models (AspireSR and SenTiva) incorporate an autostimulation feature that detects sudden increases in heart rate (ictal tachycardia) as a surrogate marker for seizure onset. When the heart rate exceeds a predefined threshold, the device delivers an additional burst of stimulation on top of the standard open-loop cycling. Key features:

• Rationale: Ictal tachycardia occurs in 80–90% of seizures and often precedes clinical manifestations by seconds; early stimulation may abort or shorten seizures
• Threshold setting: Individualized based on the patient's baseline heart rate and expected ictal tachycardia magnitude; typically set at 20–40% above resting heart rate
• Limitations: Exercise, anxiety, and other non-seizure causes of tachycardia can trigger false detections; some seizures (especially nocturnal or brief focal seizures) may not produce sufficient tachycardia
• Clinical data: Retrospective studies suggest that autostimulation may provide additional seizure reduction in some patients, particularly those with seizures associated with robust ictal tachycardia; prospective controlled data are limited

VNS in Special Populations

Pediatric Use

VNS is FDA-approved for children ≥4 years with drug-resistant focal epilepsy. Off-label use in younger children and in generalized epilepsies is common. Pediatric considerations include:

• Similar efficacy to adults, with some series reporting better response rates in children
• Implantation feasible in children as young as 1–2 years, though smaller body habitus requires careful generator placement
• Particularly useful in children with Lennox-Gastaut syndrome, Dravet syndrome, and other severe epileptic encephalopathies who are not surgical candidates

Lennox-Gastaut Syndrome and Generalized Epilepsies

Although initial FDA approval was for focal epilepsy in adults, evidence supports VNS use in generalized epilepsy syndromes. The most recent AAN guideline states that VNS "may be considered" for children with generalized and focal seizures, as well as for Lennox-Gastaut syndrome. Response rates are variable but may be comparable to those seen in focal epilepsy.

Depression and Quality of Life

VNS is independently FDA-approved for treatment-resistant depression (2005), suggesting a broader neuromodulatory effect beyond seizure control. In epilepsy patients, VNS treatment is associated with improvements in quality-of-life and mood measures, even in patients whose seizure frequency does not substantially decrease. This may be mediated by serotonergic and noradrenergic modulation through brainstem nuclei.

VNS Compared With Other Neurostimulation Therapies

Practical Considerations

• Follow-up schedule: Post-implantation office visits every 2–4 weeks during initial titration, then every 3–6 months once therapeutic parameters are established
• Battery monitoring: Generator battery status is checked at each visit; elective replacement is recommended before battery depletion to avoid loss of therapeutic effect
• Lead integrity: High impedance readings suggest lead fracture or disconnection; low impedance may indicate a short circuit; confirmed by X-ray of the lead and connections
• Explantation: If VNS is no longer needed or effective, the generator can be removed; however, leaving the lead attached to the vagus nerve is recommended to avoid the risk of nerve injury during lead removal
• Patient education: Patients should carry a VNS identification card; wear a medical alert bracelet; inform all treating physicians (especially anesthesiologists and emergency providers) about the implanted device

VNS and Mortality/SUDEP

Drug-resistant epilepsy carries a significantly elevated mortality risk, primarily driven by SUDEP. The potential of VNS to reduce this risk has important clinical implications:

• SUDEP rate in drug-resistant epilepsy: Approximately 6–9 per 1,000 patient-years in the highest-risk populations (uncontrolled generalized tonic-clonic seizures)
• VNS-treated patients: Indirect evidence suggests that SUDEP rates in VNS-treated populations may be lower than expected for similar drug-resistant epilepsy cohorts; some post hoc analyses report rates of 2–4 per 1,000 patient-years
• Proposed mechanisms: VNS may improve autonomic regulation (reducing ictal/postictal cardiac and respiratory dysfunction); chronic brainstem modulation may enhance arousal responses during postictal periods
• Caution: These are observational data with potential selection bias; no randomized trial has been powered to demonstrate SUDEP reduction with VNS; however, the indirect evidence supports that VNS treatment is associated with mortality rates lower than expected in patients with drug-resistant epilepsy

Emerging VNS Technologies

Non-Invasive VNS (nVNS)

Transcutaneous vagus nerve stimulation (tVNS) devices deliver electrical stimulation to the auricular branch of the vagus nerve through the outer ear (tragus) or to the cervical vagus nerve through skin electrodes on the neck. While FDA-cleared for migraine and cluster headache, research on tVNS for epilepsy is ongoing:

• Auricular tVNS: Multiple small trials have shown modest seizure reduction (~25–30%); not as effective as implanted VNS but has minimal side effects and requires no surgery
• Cervical tVNS (gammaCore): FDA-cleared for headache; small pilot studies in epilepsy show mixed results
• Potential role: Could serve as a non-invasive trial before committing to surgical VNS implantation; may identify patients likely to respond to vagal neuromodulation
• Current status: Not yet FDA-approved for epilepsy; investigational use only

Next-Generation Implantable VNS

Future VNS developments include miniaturized generators, improved closed-loop algorithms incorporating multiple biosignals (EEG, EMG, and cardiac), and longer battery life. Research is also exploring bilateral VNS and combined VNS with transcranial direct current stimulation (tDCS) for synergistic effects.

References

1. Friedman D, Engel J. Surgical treatments, devices, and nonmedical management of epilepsy. Continuum (Minneap Minn) 2025;31(1):165–186.
2. Ryvlin P, Rheims S, Hirsch LJ, Sokolov A, Jehi L. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol 2021;20(12):1038–1047.
3. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg 2011;115(6):1248–1255.
4. Englot DJ, Rolston JD, Wright CW, Hassnain KH, Chang EF. Rates and predictors of seizure freedom with vagus nerve stimulation for intractable epilepsy. Neurosurgery 2016;79(3):345–353.
5. Morris GL, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy. Neurology 2013;81(16):1453–1459.
6. Fisher RS, Velasco AL. Electrical brain stimulation for epilepsy. Nat Rev Neurol 2014;10(5):261–270.
7. Rheims S, Sperling MR, Ryvlin P. Drug-resistant epilepsy and mortality—why and when do neuromodulation and epilepsy surgery reduce overall mortality. Epilepsia 2022;63(12):3020–3036.
8. Ben-Menachem E, Månsson A, Kraszewski K, et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. Epilepsia 1994;35(3):616–626.
9. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 1998;51(1):48–55.
10. Hamilton P, Soryal I, Dhahri P, et al. Clinical outcomes of VNS therapy with AspireSR (including cardiac-based seizure detection) at a large complex epilepsy and surgery centre. Seizure 2018;58:120–126.
11. Wheless JW, Gienapp AJ, Ryvlin P. Vagus nerve stimulation (VNS) therapy update. Epilepsy Behav 2018;88S:2–10.
12. Granbichler CA, Zimmermann G, Oberaigner W, et al. Potential of vagus nerve stimulation to reduce SUDEP: a post hoc analysis. Epilepsy Res 2021;172:106603.